Probiotics in Animal Feed Market worth $8.76 billion by 2031- Exclusive Report by MarketsandMarkets™

MarketsandMarkets estimates the global probiotics-in-animal-feed market at USD 5.82 billion in 2026 and projects it to reach USD 8.76 billion by 2031, an 8.5% CAGR. Poultry is forecast to represent 45% of the 2026 market, bacteria-based products 79.5%, and Asia Pacific is expected to post the fastest regional growth at a 9.7% CAGR. The report cites demand for antibiotic alternatives and animal-health benefits as growth drivers, while noting formulation costs, regulatory requirements, and probiotic viability challenges.

Analysis

The investable signal is a possible shift in feed-additive mix, not a near-term earnings forecast. Probiotic adoption depends on repeatable improvements in feed conversion and animal health that outweigh formulation and handling costs; broad market forecasts do not establish that suppliers can capture attractive margins or that listed names have material exposure. Dry, processing-stable products and species-specific evidence could favor firms with fermentation, formulation and farm-level distribution capabilities, while weak field results or inconsistent viability would undermine adoption. Poultry’s scale makes it a plausible early volume channel, but this is not evidence of incremental profits for any named supplier.

The competitive read-through to NSIS.B, IFF, ADM, EVK and PAHC is therefore modest and conditional. The cited feed-enzyme activity is adjacent capability, not proof of probiotic revenue or direct demand. The Lallemand/BIO-CAT deal may increase competitive capacity, but the article does not establish the acquired business’s livestock-feed contribution. Asia-Pacific growth could expand the addressable market while also intensifying local competition and execution demands.

Near term, this promotional market estimate is unlikely to be a standalone catalyst. Over 1–3 months, watch earnings commentary for animal-nutrition growth, product launches and customer adoption; over 6–18 months, the key test is disclosed, sustained volume or mix improvement. Reversal risks include weak on-farm efficacy, processing-related viability losses, regulatory changes, and livestock/feed economics that make additive costs harder to recover. No company-level revenue, share or margin evidence supports attributing the forecast to listed firms.

Key Decisions for Investors

• No immediate directional trade: treat the market-growth estimate as an industry watch item, not a basis to buy the named stocks.
• Track NSIS.B, IFF, ADM, EVK and PAHC earnings for explicit animal-nutrition sales, probiotic launches, adoption evidence and margin commentary; do not infer livestock-feed exposure from enzyme or broader biosolutions activity.
• Revisit a long in the supplier with the clearest verified probiotic growth only after company disclosures show repeatable customer uptake and financial contribution; require evidence that margins are not being diluted by formulation or distribution costs.
• Falsify the adoption thesis if management reports stalled uptake, poor customer repeat rates, or no improvement in animal-nutrition volumes/mix despite product launches; also monitor regulatory changes and feed economics.